These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 28161220)

  • 21. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
    Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
    Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of a Pharmacist-Driven Prothrombin Complex Concentrate Protocol on Time to Administration in Patients with Warfarin-associated Intracranial Hemorrhage.
    Corio JL; Sin JH; Hayes BD; Goldstein JN; Fuh L
    West J Emerg Med; 2018 Sep; 19(5):849-854. PubMed ID: 30202498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose compared to manufacturer-recommended dose four-factor prothrombin complex concentrate for acute warfarin reversal.
    Zemrak W; Manuel F; Smith KE; Rolfe S; Hayes T; Trowbridge RL; Carlone B; Seder D
    J Thromb Thrombolysis; 2019 Feb; 47(2):263-271. PubMed ID: 30443817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of 3-Factor Versus 4-Factor Prothrombin Complex Concentrate With Regard to Warfarin Reversal, Blood Product Use, and Costs.
    DeAngelo J; Jarrell D; Cosgrove R; Camamo J; Edwards C; Patanwala AE
    Am J Ther; 2018; 25(3):e326-e332. PubMed ID: 28763307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of thromboembolic events following administration of four-factor prothrombin complex concentrate (4F-PCC) for oral anticoagulation reversal.
    Makhoul T; Kelly G; Kersten B; Nadler M; Zammit CG; Jones CMC; Scott R; Acquisto NM
    Thromb Res; 2020 Oct; 194():158-164. PubMed ID: 32788109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discussion of "Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa".
    Van Dusen R
    Am J Surg; 2018 May; 215(5):780-781. PubMed ID: 29366484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjusted versus actual body weight dosing of 4-factor prothrombin complex concentrate in obese patients with warfarin-associated major bleeding.
    Smetana KS; Ziemba R; May CC; Erdman MJ; Van Matre ET; Jones GM
    J Thromb Thrombolysis; 2019 Apr; 47(3):369-374. PubMed ID: 30460443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding.
    Cabral KP; Fraser GL; Duprey J; Gibbons BA; Hayes T; Florman JE; Seder DB
    Clin Neurol Neurosurg; 2013 Jun; 115(6):770-4. PubMed ID: 22835715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of Temporary Warfarin Reversal in Patients With Left Ventricular Assist Devices: the KVAD Study.
    Sylvester KW; Grandoni J; Rhoten M; Coakley L; Lyons-Matiello E; Frankel K; Fortin B; Jolley K; Park HS; Freedman RY; Mehra MR; Givertz MM; Connors JM
    J Card Fail; 2024 Sep; 30(9):1111-1119. PubMed ID: 38521486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 3-Factor Versus 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal in Severe Bleeding: A Multicenter, Retrospective, Propensity-Matched Pilot Study.
    Jones GM; Erdman MJ; Smetana KS; Mohrien KM; Vandigo JE; Elijovich L
    J Thromb Thrombolysis; 2016 Jul; 42(1):19-26. PubMed ID: 26721625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Four-factor prothrombin complex concentrate dose response relationship with INR for warfarin reversal.
    Yohe AS; Livings SE
    Am J Emerg Med; 2019 Aug; 37(8):1534-1538. PubMed ID: 31130370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of Venous Thromboembolism After Receiving Prothrombin Complex Concentrate for Warfarin-associated Intracranial Hemorrhage.
    Felton D; Foley EM; Traub SJ; Vodonos A; Ganetsky M
    J Emerg Med; 2016 Jan; 50(1):1-6. PubMed ID: 26409668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Propensity score adjusted comparison of three-factor versus four-factor prothrombin complex concentrate for emergent warfarin reversal: a retrospective cohort study.
    Margraf DJ; Seaburg S; Beilman GJ; Wolfson J; Gipson JC; Chapman SA
    BMC Emerg Med; 2020 Nov; 20(1):93. PubMed ID: 33243152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High versus low fixed-dose four factor-prothrombin complex concentrate for warfarin reversal in patients with intracranial hemorrhage.
    Compton F; Hall J; De Simone N; Usmani A; Sarode R; Burner J
    Transfus Apher Sci; 2022 Oct; 61(5):103444. PubMed ID: 35414467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective Evaluation of a Fixed-Dose 4-Factor Prothrombin Complex Concentrate Protocol for Urgent Vitamin K Antagonist Reversal.
    Bitonti MT; Rumbarger RL; Absher RK; Curran LM
    J Emerg Med; 2020 Feb; 58(2):324-329. PubMed ID: 31787372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding.
    Go AS; Leong TK; Sung SH; Wei R; Harrison TN; Gupta N; Baker N; Goldstein B; Ataher Q; Solomon MD; Reynolds K;
    J Thromb Thrombolysis; 2022 Oct; 54(3):470-479. PubMed ID: 35984591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of thromboembolic events after protocolized warfarin reversal with 3-factor PCC and factor VIIa.
    Barton CA; Johnson NB; Case J; Warden B; Hughes D; Zimmerman J; Roberti G; McMillian WD; Schreiber M
    Am J Emerg Med; 2015 Nov; 33(11):1562-6. PubMed ID: 26143317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding.
    Rech MA; Masic D; Hammond DA
    West J Emerg Med; 2021 Feb; 22(2):163-169. PubMed ID: 33856296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experiences with an activated 4-factor prothrombin complex concentrate (FEIBA) for reversal of warfarin-related bleeding.
    Stewart WS; Pettit H
    Am J Emerg Med; 2013 Aug; 31(8):1251-4. PubMed ID: 23763937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 3-Factor versus 4-Factor Prothrombin Complex Concentrates for the Reversal of Vitamin K Antagonist-Associated Coagulopathy: A Systematic Review and Meta-analysis.
    Puchstein D; Kork F; Schöchl H; Rayatdoost F; Grottke O
    Thromb Haemost; 2023 Jan; 123(1):40-53. PubMed ID: 36626899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.